Ariad Pharmaceutical Now Covered by Analysts at Citigroup. (ARIA)

Citigroup assumed coverage on shares of Ariad Pharmaceutical (NASDAQ: ARIA) in a report released on Thursday. The firm issued a buy rating and a $31.00 target price on the stock. “We believe ARIA’s ponatinib is “best in class” in the ~$5bn WW …

Share